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ABSTRACT
Background: Chronic airway inflammation is a basic pathology of bronchial asthma and it is important to con-
trol the inflammation by anti-inflammatory therapy mainly with steroids. However, in asthma in the elderly, there
are cases where physicians hesitate to introduce the inhaled corticosteroid (ICS) therapy based on the diagno-
sis that the use of inhalants is difficult due to the existence of a functional lesion accompanying asthma.
Methods & Results: In cases where self-administrated inhalation therapy is difficult to execute due to the ac-
companiment of a functional lesion and in cases where sufficient curative effects of steroids are not produced in
self-inhalation, administration of assisted inhalation resulted in improvement of clinical symptoms and pulmo-
nary function and was proven effective.
Conclusions: Assisted inhalation therapy is expected to be useful in general and also in terms of expanding
the application of ICS in the asthma in the elderly.
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INTRODUCTION
A basic pathology in bronchial asthma is chronic air-
way inflammation , in which various cells such as
eosinophils, lymphocytes, mast cells, and airway epi-
thelial cells and various cytokines, chemokines, and
inflammatory mediators produced from them are in-
volved.1 In addition, chronic airway inflammation is
also involved in the enhancement of airway hyperre-
sponsiveness , which is another pathology of bron-
chial asthma.2,3 Therefore the basics of the therapy
against bronchial asthma is to control inflammation
caused by these wide range of cells and the drug of
first alternative at this point is inhaled corticosteroids
(ICS). ICS improves enhancement of airway hyperre-
sponsiveness as well as controls airway inflammation
by their powerful anti-inflammation action.3 ICS are
positioned as the drug of first choice for asthma con-
trollers in the 2002 GINA Guidelines as well.4
Devices for inhalants are developed assuming that
the circumstances where patients use inhalants by
themselves . In actual clinical conditions , however ,
there are cases where physicians hesitate to intro-
duce ICS therapy because of the diagnosis that the
use of inhalants is difficult due to the accompaniment
of a functional lesion, and asthma cases where suffi-
cient curative effects of steroids are not produced in
self- inhalation mostly among the elderly . Even in
such cases , however , we experience cases where
asthma control is improved with execution of accu-
rately manipulated ICS therapy assisted by a
caregiver for a part of the inhalation procedure
(Fig. 1). Such being the case , this paper presents
handicapped elderly asthma cases where clinical
symptoms and pulmonary functions were improved
by providing assistance for inhalation to discuss prob-
lems in inhalation therapy against asthma in the eld-
erly . Written informed consent was obtained from
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Fig. 1  Actual Assisted Inhalation Therapy. An asthma 
case where self-inhalation is impossible due to finger defor-
mation associated with rheumatoid arthritis. A caregiver wil 
spray the inhalant in a timely manner for the patient’ s inspi-
ration and make sure of the inhalation condition.
both patients.
CLINICAL SUMMARY
CASE 1
Case: 81-year-old, woman
Chief complaints: Wheezing, coughing, sputum
Past history: She suffered from infantile asthma un-
til nine years of age and has been suffering from
rheumatoid arthritis since the age of 50.
Personal history: She has no smoking history, and
occasionally drinks alcohol.
History of the present illness: The patient has been
aware of coughing, sputum, and wheezing developing
mostly during the night and continuing to the early
morning for approximately four years and was treated
with cough suppressants after being diagnosed as
suffering from chronic bronchitis. After being admit-
ted to our hospital for work-up of low back pain and
rehabilitation, the patient was referred to our depart-
ment for work-up of coughing.
Laboratory findings : FVC ( forced vital capacity )
1.49 (L), FEV1.0 (forced expiratory volume in one sec-
ond) 1.05 (L), FEV1.0% 70.5 (%), %FEV1.0 62.5 (%),
%PEF (Peak expiratory flow) 50.2 (%)
Clinical course: With bronchial asthma suspected
from the clinical history , administration of inhala-
tional β2 stimulants and monitoring of PEF under as-
sistance started. We used the predicted PEF values in
the Japanese report by Tsukioka et al.5 After admini-
stration of inhalational β2 stimulants, %PEF value re-
versed by approximately 20% and symptoms im-
proved with no other cardiopulmonary diseases ac-
companied, the patient was diagnosed as suffering
from bronchial asthma. Thus, self-administrated ICS
therapy with 400 μg day of hydrofluoroalkane-
beclometasone (HFA-BDP) was started. With no im-
provement recognized both in the subjective symp-
toms and in the %PEF, which remained on the order
of 59.1%, after eight weeks passed since the introduc-
tion of the ICS therapy, inhalation guidance was pro-
vided again, where it was found that inhalation was
conducted with an inaccurate technique. Because it
was considered difficult for the patient to manipulate
inhaled steroids on her own due to a swan-neck de-
formity resulting from rheumatoid arthritis recog-
nized in the inter-phalangeal joints, we introduced ad-
ministration of assistance for inhalation with the co-
operation of the patient’s family. After administration
of assistance for eight weeks, the clinical symptoms
disappeared almost completely and the %PEF relative
to the predictive values improved from approximately
59% to 90% (Fig. 2).
PATHOLOGICAL FINDINGS
CASE 2
Case: 82-year-old, woman
Chief complaints: Wheezing, dyspnea, insomnia
Past history: She suffered from asthma since the
age of 70 and has been suffering from vascular de-
mentia since the age of 76.
Personal history: She has no smoking history, and
occasionally drinks alcohol.
History of the present illness: The patient became
aware of paroxysmal dyspnea since the 70 years of
age. Diagnosed as suffering from asthma by a gen-
eral physician, the patient was receiving treatment
with a theophylline drug . From approximately six
months prior to admission, the frequency of wheez-
ing and paroxysmal dyspnea increased and the pa-
tient became aware of insomnia due to nighttime
asthma symptoms on several occasions a week. The
patient was additionally administered with a patch-
type β2 stimulant but no sufficient improvement was
noted in the asthma symptoms. The patient was re-
ferred to our hospital for the purpose of controlling
the asthma.
Laboratory findings: FVC 1.48 (L), FEV1.0 1.12 (L),
FEV1.0% 75.7 (%), %FEV1.0 59.1 (%), %PEF 40.2 (%)
Clinical course: After administration of inhalational
β2 stimulants, FEV1.0 improved by approximately 280
ml with no simultaneous onset of other cardiopul-
monary diseases recognized in blood tests, thoracic
radiographs , and electrocardiography . From the
above findings, the asthma was diagnosed as being
under control. With no problem in the patient’s short
term memory notwithstanding the accompaniment of
vascular dementia , self-administrated ICS therapy
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Fig. 2 Clinical Course of Case 1. PEF: peak expiratory flow; ODU: on demand 
use; ICS: inhaled corticosteroid; HFA-BDP: hydrofluoroalkane-beclometasone
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was diagnosed as possible in inhalation guidance by a
physician and ICS therapy with 400 μgday of flutica-
sone propionate (FP) was introduced . In order to
monitor the pulmonary function, the PEF values were
measured by the physician three times from 9:00 to
11:00 in the morning and the highest value indicated
in the measurement was regarded as the PEF value
at that point. No improvements were recognized both
in the subjective symptoms and in the %PEF, which
remained on the order of 39.1%, after eight weeks
passed since the introduction of the self-
administrated ICS therapy. Inhalation guidance was
provided again, where it was found that inhalation
was conducted not only with an inaccurate technique
but also in poor compliance with the prescription. To
cope with the situation, assisted ICS therapy with a
FP introduced under the cooperation of her family
was administered with the objective of continuing in-
halation with an accurate technique . After eight
weeks of assisted administration of FP, insomnia as-
sociated with the asthma symptoms developing dur-
ing the night time as well as the wheezing and dysp-
nea disappeared. The %PEF relative to the predictive
value also improved from approximately 42% to 76%
(Fig. 3).
DISCUSSION
In a case where self inhalation therapy is difficult to
perform due to motor dysfunction associated with
rheumatoid arthritis, and in a case where a problem
was recognized in the inhalation technique and in the
compliance to the prescription due to intellectual dis-
ability associated with vascular dementia, execution
of assisted ICS therapy resulted in improvement in
the clinical symptoms and the pulmonary function pa-
rameters.
It has been proven in many clinical studies that pe-
riodical use of ICS for persistent asthma results in im-
provement in pulmonary function , improvement in
airway hyperresponsiveness, improvement in asthma
symptoms, improvement in frequency and severity of
attacks, and improvement in QOL.6-9 In order to pro-
duce sufficient curative effects of ICS therapy, inhala-
tion by an accurate technique is imperative . 4 It is
often experienced, however , that complications ac-
companying asthma inhibit the inhalation technique
in cases of asthma mostly in the elderly. While intel-
lectual disability is a complication causing lack of un-
derstanding about the inhalation technique , motor
dysfunction is a complication resulting in impairment
of the inhalation technique. An inaccurate inhalation
technique will not bring about improvement in
asthma control because it will not produce sufficient
curative effects of inhaled steroids, which may also
result in lowering of compliance to an inhalation pre-
scription. Assisted inhalation therapy is “an inhalation
therapy performed with the assistance of caregivers
for patients with diseases for which the therapy is in-
dicated, in cases that the patients have difficulty in in-
halation by themselves due to some functional disor-
ders ” . Introduction of assisted ICS therapy is ex-
pected to be useful for improvement of asthma con-
trol in handicapped persons, in cases where self inha-
lation therapy is difficult to execute due to accompani-
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Fig. 3 Clinical Course of Case 2. PEF: peak expiratory flow; ODU: on demand 
use; ICS: inhaled corticosteroid; FP: fluticasone propionate
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ment of a functional lesion or in cases where suffi-
cient curative effects of steroids are not produced in
self- inhalation, as presented this time. In the future,
more handicapped asthma cases, for which the as-
sisted ICS therapy is applicable, need to be accumu-
lated to prove the clinical utility of assistance for inha-
lation.
The asthma mortality in the Japanese population,
which continued to be on the order of approximately
6,000 people per annum in the early 1990s, has im-
proved to less than 4,000 people per annum in the re-
cent years . 10 The prevalence of anti-inflammatory
therapy mostly with ICS is considered to have made a
substantial contribution to the decrease in the asthma
mortality.11 On the contrary, according to a study on
the change of asthma mortalities by generation over
the years, however, the asthma mortality in the eld-
erly aged 80 or higher has been increasing.12 Chronic
airway inflammation is a basic pathology of asthma in
the elderly too and therefore it is important to control
the inflammation by a therapy centering on ICS. How-
ever, it has been pointed out that the usage of ICS is
extremely low in asthma in the elderly.13,14 Assisted
inhalation therapy is expected to be useful also in
terms of expanding the application of ICS in the
asthma in the elderly.
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